The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Official Title: A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma
Study ID: NCT00051025
Brief Summary: The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Central Baptist Hospital, Lexington, Kentucky, United States
Hematology and Oncology Services, Metairie, Louisiana, United States
Name: Elyane Lombardy, M.D.
Affiliation: Ligand Pharmaceuticals
Role: STUDY_DIRECTOR